PALO ALTO, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Auransa, Inc., an artificial intelligence (AI)-driven pharmaceutical company developing precision medicines in areas of significant unmet medical need, today announced the company’s participation at the upcoming BioCentury-BayHelix China Healthcare Summit 2018. Pek Lum, Ph.D., the company’s co-founder and chief executive officer, will participate in a roundtable panel discussion examining the potential for the China healthcare industry to successfully leverage AI to build global digital health companies. Additionally, company management will take part in 1-on-1 meetings at the conference, which is being held November 13-14 in Shanghai, China.
Details of the roundtable panel discussion are as follows:
| Session Title: | China’s Globalization Challenge: Leveraging Its AI Future |
| Date: | Tuesday, November 13, 2018 |
| Time: | 2:10 – 3:10 p.m. (local time) |
| Participants: | Pek Lum, Ph.D., Co-founder and CEO, Auransa |
| Stanley Li, M.D., Founder, DXY (Session Chair) | |
| Andrea de Souza, Senior Director, Informatics, Eli Lilly (Moderator) | |
| Chengming GU, M.D., VP, Medical Affairs, Greater China Region, Pfizer | |
| Mao Mao, Ph.D., Founder and CEO, SeekIn | |
| Tony Zhang, Founder and CEO, LinkDoc Technology (Beijing) Co. | |
| Alex Zhavoronkov, Ph.D., Co-founder and CEO, Insilico Medicine |
Additionally, Dr. Lum will be joined by members of the Auransa management team to provide introductions to Auransa and how the company is combining its proprietary SMarTR™ Engine, a powerful predictive platform, with broad drug discovery and development expertise, to redefine precision medicine. To request a meeting with Auransa at the China Healthcare Summit 2018, please contact Andrew Wong, Auransa’s senior vice president of corporate business development at andrew@auransa.com, or Stephanie Diaz of Vida Strategic Partners at sdiaz@vidasp.com.
About Auransa
Founded in 2014, Auransa is an artificial intelligence (AI)-driven pharmaceutical company developing precision medicines in areas of significant unmet medical need. The company is working to redefine precision medicine by combining a sophisticated, proprietary predictive computational platform with traditional pharmaceutical industry experience. The company’s SMarTR™ Engine, which leverages machine learning, advanced analytics and mathematics in an AI framework, and its CTSeek™ liquid biopsy diagnostic technology, generate insights from molecular data for a deep understanding of disease biology and patient subtypes. This information, when paired with the company’s breadth of in-house drug discovery and development expertise, drives the identification of novel compounds designed to most effectively address significant unmet medical needs for clinically meaningful disease subtypes. The company has successfully generated a broad pipeline of drug candidates including programs addressing cancer, neurology, inflammation, infectious disease and metabolic disease that are advancing toward investigational new drug (IND) filings. For more information, please visit: www.auransa.com.